Skip to main content
PMC home page
Japanese Journal of Cancer Research : Gann logoLink to Japanese Journal of Cancer Research : Gann
. 1993 Feb;84(2):147–152. doi: 10.1111/j.1349-7006.1993.tb02848.x

Construction of Immunoradiometric Assay for Circulating c‐erbB‐2 Protooncogene Product in Advanced Breast Cancer Patients

Makoto Hosono 1,✉, Tsuneo Saga 1, Harumi Sakahara 1, Hisataka Kobayashi 1, Makoto Shirato 1, Keigo Endo 2, Tadashi Yamamoto 3, Tetsu Akiyama 4, Kumao Toyoshima 4, Junji Konishi 1
PMCID: PMC5919131  PMID: 8096502

Abstract

The human c‐erbB‐2 protooncogene product (erbB‐2 protein) is a 185 kilodalton glycoprotein closely related to epidermal growth factor receptor protein. In this study, we measured the concentration of circulating erbB‐2 protein in cancer patients by means of a new immunoradiometric assay (IRMA). Two monoclonal antibodies (MoAbs), SV2‐61γ and 6G10, recognize erbB‐2 protein but bind to separate epitopes. SV2‐61γ was used as an immunoadsorbent and 6G10 as an 125I‐labeled probe. A serum was considered positive for erbB‐2 protein if the percent binding exceeded the mean of the normal group by more than 3 standard deviations. Eleven of 21 patients with advanced breast cancer and 1 of 15 with advanced gastric cancer were positive. Serum erbB‐2 protein levels correlated well with the therapy and the status of the patients with breast cancer. On the contrary, all patients with advanced colon, ovarian, or pancreatic cancers, showed levels below the cut‐off value. These results suggest that circulating erbB‐2 protein can be measured using the newly constructed IRMA. Since c‐erbB‐2 protooncogene amplification and overexpression are accepted as a good marker of aggressiveness, relapsing potency, and poor prognosis, this IRMA should be a promising tool with which to help manage breast cancer patients.

Keywords: Tumor marker, c‐erbB‐2 product, — Immunoradiometric assay, Breast cancer

Full Text

The Full Text of this article is available as a PDF (301.3 KB).

REFERENCES

  • 1. ) Akiyama , T. , Sudo , C. , Ogawa , H. , Toyoshima , K. and Yamamoto , T.The product of the human c‐erbB‐2 gene: a 185 kilodalton glycoprotein with tyrosine kinase activity . Science , 232 , 1644 – 1646 ( 1986. ). [DOI] [PubMed] [Google Scholar]
  • 2. ) Saga , T. , Endo , K. , Akiyama , T. , Sakahara , H. , Koizumi , M. , Watanabe , Y. , Nakai , T. , Hosono , M. , Yamamoto , T. , Toyoshima , K. and Konishi , J.Scintigraphic detection of overexpressed c‐erbB‐2 protooncogene products by a class‐switched murine anti‐c‐erbB‐2 protein monoclonal antibody . Cancer Res. , 51 , 990 – 994 ( 1991. ). [PubMed] [Google Scholar]
  • 3. ) Mori , S. , Mori , Y. , Mukaiyama , T. , Yamada , Y. , Sonobe , Y. , Matsushita , H. , Sakamoto , G. , Akiyama , T. , Ogawa , M. , Shiraishi , M. , Toyoshima , K. and Yamamoto , T.In vitro and in vivo release of soluble erbB‐2 protein from human carcinoma cells . Jpn. J. Cancer Res. , 81 , 489 – 494 ( 1990. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4. ) Libermann , T. A. , Nusbaum , H. R. , Razon , N. , Kris , R. , Lax , I. , Soreq , H. , Whittle , N. , Waterfield , M. D. , Ullrich , A. and Schlessinger , J.Amplification, enhanced expression, and possible rearrangement of EGF receptor gene in primary human brain tumors of glial origin . Nature , 313 , 144 – 147 ( 1985. ). [DOI] [PubMed] [Google Scholar]
  • 5. ) Yamamoto , T. , Kamata , N. , Kawano , H. , Shimizu , S. , Kuroki , T. , Toyoshima , K. , Rikimaru , K. , Nomura , N. , Ishizaki , R. , Pastan , I. , Gamou , S. and Shimizu , N.High incidence of amplification of the epidermal growth factor receptor gene in human squamous carcinoma cell lines . Cancer Res. , 46 , 414 – 416 ( 1986. ). [PubMed] [Google Scholar]
  • 6. ) Ozawa , S. , Ueda , M. , Ando , N. , Abe , O. and Shimizu , N.Epidermal growth factor receptors in cancer tissues of esophagus, lung, pancreas, colorectum, breast and stomach . Jpn. J. Cancer Res. , 79 , 1201 – 1207 ( 1988. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7. ) Dati , C. , Muraca , R. , Tazartes , O. , Antoniotti , S. , Perroteau , I. , Giai , M. , Cortese , P. , Sismondi , P. , Saglio , G. and De Bortoli , M.c‐erbB‐2 and ras expression levels in breast cancer are correlated and show a co‐operative association with unfavorable clinical outcome . Int. J. Cancer , 47 , 833 – 838 ( 1991. ). [DOI] [PubMed] [Google Scholar]
  • 8. ) Gullick , W. J. , Love , S. B. , Wright , C. , Barnes , D. M. , Guesterson , B. , Harris , A. L. and Altman , D. G.c‐erbB‐2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes . Br. J. Cancer , 63 , 434 – 438 ( 1991. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9. ) Gusterson , B. A. , Machin , L. G. , Gullick , W. J. , Gibbs , N. M. , Powles , T. J. , Elliott , C. , Ashley , S. , Monaghan , P. and Harrison , S.c‐erbB‐2 expression in benign and malignant breast disease . Br. J. Cancer , 58 , 453 – 457 ( 1988. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10. ) Winstanley , J. , Cooke , T. , Murray , G. D. , Platt‐Higgins , A. , George , W. D. , Holt , S. , Myskov , M. , Spedding , A. , Barraclough , B. R. and Rudland , P. S.The long term prognostic significance of c‐erbB‐2 in primary breast cancer . Br. J. Cancer , 63 , 447 – 450 ( 1991. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11. ) Yonemura , Y. , Ninomiya , I. , Yamaguchi , A. , Fushida , S. , Kimura , H. , Ohoyama , S. , Miyazaki , I. , Endou , Y. , Tanaka , M. and Sasaki , T.Evaluation of immunoreactivity for erbB‐2 protein as a marker of poor short term prognosis in gastric cancer . Cancer Res. , 51 , 1034 – 1038 ( 1991. ). [PubMed] [Google Scholar]
  • 12. ) Yu , F. Z. , Sugano , K. , Ohkura , H. and Mori , S.Development of sandwich radioimmunometric assay for serum c‐erbB‐2 oncogene product and its significance on diagnosing breast carcinoma . Jpn. J. Clin. Pathol. , 39 , 1087 – 1092 ( 1991. ). [PubMed] [Google Scholar]
  • 13. ) Masuko , T. , Sugahara , K. , Kozono , M. , Otsuki , S. , Akiyama , T. , Yamamoto , T. , Toyoshima , K. and Hashimoto , Y.A murine monoclonal antibody that recognizes an extracellular domain of the human c‐erbB‐2 protooncogene product . Jpn. J. Cancer Res. , 80 , 10 – 14 ( 1989. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14. ) Hilkens , J. , Buijs , F. , Hilgers , J. , Hageman , P. H. , Calafat , J. , Sonnenberg , A. and Van der Valk , M.Monoclonal antibodies against human milk‐fat globule membranes detecting differentiation antigens of the mammary gland and its tumors . Int. J. Cancer , 34 , 197 – 206 ( 1984. ). [DOI] [PubMed] [Google Scholar]
  • 15. ) Kufe , D. , Inghirami , G. , Abe , M. , Hayes , D. , Justi‐Wheeler , H. and Schlom , J.Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors . Hybridoma , 3 , 223 – 231 ( 1984. ). [DOI] [PubMed] [Google Scholar]
  • 16. ) Holmes , W. E. , Sliwkowski , M. X. , Akita , R. W. , Henzel , W. J. , Lee , J. , Park , J. W. , Yansura , D. , Abadi , N. , Raab , H. , Lewis , G. D. , Shepard , H. M. , Kuang , W.‐J. , Wood , W. I. , Goeddel , D. V. and Vandlen , R. L.Identification of heregulin, a specific activator of p185 erbB2 . Science , 256 , 1205 – 1210 ( 1992. ). [DOI] [PubMed] [Google Scholar]
  • 17. ) Zhou , D. , Battifora , H. , Yokota , J. , Yamamoto , T. and Cline , M. J.Association of multiple copies of the c‐erbB‐2 oncogene with spread of breast cancer . Cancer Res. , 47 , 6123 – 6125 ( 1987. ). [PubMed] [Google Scholar]
  • 18. ) Coombs , L. M. , Pigott , D. A. , Sweeney , E. , Proctor , A. J. , Eydmann , M. E. , Parkinson , C. and Knowels , M. A.Amplification and over‐expression of c‐erbB‐2 in transitional cell carcinoma of the urinary bladder . Br. J. Cancer , 63 , 601 – 608 ( 1991. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19. ) McCann , A. H. , Dervan , P. A. , O'Regan , M. , Codd , M. B. , Guillick , W. J. , Tobin , B. M. J. and Carney , D. N.Prognostic significance of c‐erbB‐2 and estrogen receptor status in human breast cancer . Cancer Res. , 51 , 3296 – 3303 ( 1991. ). [PubMed] [Google Scholar]
  • 20. ) Paterson , M. C. , Dietrich , K. D. , Danyluk , J. , Paterson , A. H. G. , Lees , A. W. , Jamil , N. , Hanson , J. , Jenkins , H. , Kause , B. E. , MacBlain , W. A. , Slamon , D. J. and Fourney , R. M.Correlation between c‐erbB‐2 amplification and risk of recurrent disease in node‐negative breast cancer . Cancer Res. , 51 , 556 – 567 ( 1991. ). [PubMed] [Google Scholar]
  • 21. ) Barnes , D. M. , Lammie , G. A. , Millis , R. R. , Gullick , W. L. , Allen , D. S. and Altaian , D. G.An immunohistochemical evaluation of c‐erbB‐2 expression in human breast carcinoma . Br. J. Cancer , 58 , 448 – 452 ( 1988. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22. ) O'Reilly , S. M. , Barnes , D. M. , Camplejohn , R. S. , Bartkova , J. , Gregory , W. M. and Richards , M. A.The relationship between c‐erbB‐2 expression, S‐phase fraction and prognosis in breast cancer . Br. J. Cancer , 63 , 444 – 446 ( 1991. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23. ) Hayes , D. F. , Sekine , H. , Ohno , T. , Abe , M. , Keefe , K. and Kufe , D. W.Use of a murine monoclonal antibody for detection of circulating plasma DF3 antigen levels in breast cancer patients . J. Clin. Invest. , 75 , 1671 – 1678 ( 1985. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24. ) Colomer , R. , Ruibal , A. , Genolla , J. and Salvador , L.Circulating CA15‐3 antigen levels in non‐mammary malignancies . Br. J. Cancer , 59 , 283 – 286 ( 1989. ). [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Japanese Journal of Cancer Research : Gann are provided here courtesy of Wiley

RESOURCES